AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16669847 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg twice daily for 5 days)
Number of subjects: 8
Study 16669847 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (100 mg twice daily for 5 days)
Number of subjects: 8
Study 16669847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study 12525736 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (TL) at doses up to 200 mg/d
Number of subjects: 20
Study 10978246 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 50
Study 10978246 — intervention group
Group type: COMPARATOR
Intervention: Nonfat isocaloric meal
Number of subjects: 50
Study 8826285 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeder standing position
Number of subjects: 0
Study 8826285 — intervention group
Group type: COMPARATOR
Intervention: Feeder sitting position
Number of subjects: 0
Study 1425819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with bromocriptine and levodopa
Number of subjects: 0
Study 1425819 — intervention group
Group type: COMPARATOR
Intervention: Levodopa monotherapy
Number of subjects: 0
Study 3939673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg bid)
Number of subjects: 733
Study 3939673 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 733
Study 3939673 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 733
Study 3939673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 30412607 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 220
Study 30412607 — intervention group
Group type: COMPARATOR
Intervention: Postconditioning
Number of subjects: 220
Study 30412607 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured myocardium
Number of subjects: 220
Study 30412607 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MCE injured myocardium
Number of subjects: 220
Study 30412607 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger infarction
Number of subjects: 220
Study 26757318 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage intervention (one massage per night for two or three nights)
Number of subjects: 78
Study 26757318 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 78
Study 24799539 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-Tailored Facilitation Intervention (Early practices)
Number of subjects: 30
Study 24799539 — intervention group
Group type: COMPARATOR
Intervention: Practice-Tailored Facilitation Intervention (Late practices)
Number of subjects: 30
Study 24799539 — intervention group
Group type: COMPARATOR
Intervention: Baseline performance (Early practices)
Number of subjects: 30
Study 24799539 — intervention group
Group type: COMPARATOR
Intervention: Baseline performance (Late practices)
Number of subjects: 30
Study 24799539 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall improvement after 6-month intervention
Number of subjects: 30
Study 22652593 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF 10 μg/kg per day intravenously for 5 consecutive days
Number of subjects: 24
Study 22652593 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar treatments without G-CSF)
Number of subjects: 24
Study 20028939 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diazoxide at bedtime
Number of subjects: 41
Study 20028939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 18541589 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (3 g CaCO3 daily, providing 1200 mg elemental Ca)
Number of subjects: 930
Study 18541589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study 18541589 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 930
Study 15168290 — intervention group
Group type: EXPERIMENTAL
Intervention: V.A.C. (KCI, Austria)
Number of subjects: 1
Study 15168290 — intervention group
Group type: COMPARATOR
Intervention: Flammazine (Smith and Nephew, Germany)
Number of subjects: 1
Study 11032056 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Number of subjects: 258
Study 11032056 — intervention group
Group type: COMPARATOR
Intervention: Dithranol cream
Number of subjects: 258
Study 9315062 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (BCT)
Number of subjects: 184
Study 9315062 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy (M)
Number of subjects: 184
Study 8421798 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP infusion (0.3 microliter per kilogram) during 15 to 30 minutes within one hour of anesthetic induction
Number of subjects: 11
Study 8421798 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 11
Study 2430084 — intervention group
Group type: EXPERIMENTAL
Intervention: 7S immunoglobulin G (400 mg IgG/kg body weight over 5 days)
Number of subjects: 20
Study 2430084 — intervention group
Group type: COMPARATOR
Intervention: 5S immunoglobulin G (400 mg IgG/kg body weight over 5 days)
Number of subjects: 20
Study 29796857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-education (strength training of the non-injured leg)
Number of subjects: 43
Study 29796857 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 43
Study 27015889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 459
Study 27015889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 27015889 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL tools (PGA, Kansas City Cardiomyopathy Questionnaire, EuroQoL‐5D)
Number of subjects: 459
Study 27015889 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MWT
Number of subjects: 459
Study 23800990 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related dysfunctional beliefs
Number of subjects: 410
Study 23800990 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 410
Study 22730940 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based motivational interviewing program
Number of subjects: 38
Study 22730940 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study 19852658 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional elastomeric ligatures
Number of subjects: 9
Study 19852658 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Slick elastomeric ligatures
Number of subjects: 9
Study 18417741 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 50 IU/kg three times per week
Number of subjects: 38
Study 18417741 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 10,000 IU once weekly
Number of subjects: 38
Study 18417741 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 20,000 IU every 2 weeks for 36 days
Number of subjects: 38
Study 18417741 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU every 4 weeks for 64 days
Number of subjects: 38
Study 18417741 — intervention group
Group type: COMPARATOR
Intervention: All regimens
Number of subjects: 38
Study 16184544 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab 20 mg on days 0 and 4; tacrolimus delayed until renal function improved
Number of subjects: 45
Study 16184544 — intervention group
Group type: COMPARATOR
Intervention: Control group (no basiliximab; tacrolimus on first postoperative day)
Number of subjects: 45
Study 12538202 — intervention group
Group type: EXPERIMENTAL
Intervention: Minute sphere acupressure
Number of subjects: 53
Study 12538202 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 53
Study 10749154 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontalis muscle flap advancement technique
Number of subjects: 8
Study 8650419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory respiratory rehabilitation (2 hours per session, 3 times per week for 7 weeks)
Number of subjects: 88
Study 8650419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory respiratory rehabilitation
Number of subjects: 88
Study 1517943 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone for 4 weeks
Number of subjects: 17
Study 1517943 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone for 8 weeks
Number of subjects: 17
Study 1517943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1517943 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 17
Study 6611026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach to substance abuse prevention (20 sessions) implemented by peer leaders
Number of subjects: 1311
Study 6611026 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral approach to substance abuse prevention (20 sessions)
Number of subjects: 1311
Study 30668478 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral training with non-dominant hand
Number of subjects: 0
Study 30668478 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral training with both hands
Number of subjects: 0
Study 29949584 — intervention group
Group type: EXPERIMENTAL
Intervention: High rebound mattress topper (HR)
Number of subjects: 30
Study 29949584 — intervention group
Group type: COMPARATOR
Intervention: Low rebound mattress topper (LR)
Number of subjects: 30
Study 27348271 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out palliative care consultation
Number of subjects: 12000
Study 27348271 — intervention group
Group type: COMPARATOR
Intervention: Opt-in palliative care consultation
Number of subjects: 12000
Study 25190617 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored duration of ECS therapy following an initial therapeutic period of 6 months
Number of subjects: 864
Study 25190617 — intervention group
Group type: COMPARATOR
Intervention: Standard duration of ECS therapy for 24 months
Number of subjects: 864
Study 22242967 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg daily for 9 days (regimen A)
Number of subjects: 39
Study 22242967 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (regimen B)
Number of subjects: 39
Study 22242967 — intervention group
Group type: COMPARATOR
Intervention: Comparison of regimen A to regimen B
Number of subjects: 39
Study 19464001 — intervention group
Group type: EXPERIMENTAL
Intervention: P(4) + oral E(2) valerate
Number of subjects: 274
Study 19464001 — intervention group
Group type: COMPARATOR
Intervention: P(4) only
Number of subjects: 274
Study 19464001 — intervention group
Group type: EXPERIMENTAL
Intervention: P(4) + hCG
Number of subjects: 274
Study 17149589 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week exercise programme (n = 10)
Number of subjects: 17
Study 17149589 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 17
Study 15082189 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 0
Study 15082189 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol consumption)
Number of subjects: 0
Study 11239528 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD
Number of subjects: 11
Study 9127916 — intervention group
Group type: EXPERIMENTAL
Intervention: Active back rehabilitation program
Number of subjects: 41
Study 9127916 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 41
Study 7953888 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 315
Study 7953888 — intervention group
Group type: EXPERIMENTAL
Intervention: Gm‐CSF
Number of subjects: 315
Study 7953888 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF and Gm‐CSF
Number of subjects: 315
Study 7953888 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic factors
Number of subjects: 315
Study 3310744 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 38
Study 3310744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29154814 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquarobic exercise
Number of subjects: 40
Study 29154814 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquarobic exercise and burdock intake combination
Number of subjects: 40
Study 29154814 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 29154814 — intervention group
Group type: EXPERIMENTAL
Intervention: Burdock intake
Number of subjects: 40
Study 25878053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SPT)
Number of subjects: 1806
Study 25878053 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 1806
Study 25878053 — intervention group
Group type: COMPARATOR
Intervention: Memory training (active control)
Number of subjects: 1806
Study 24977154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp Turning (ST)
Number of subjects: 29
Study 24977154 — intervention group
Group type: COMPARATOR
Intervention: Corner Turning (CT)
Number of subjects: 29
Study 22394041 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-gripping mesh
Number of subjects: 50
Study 22394041 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue mesh fixation
Number of subjects: 50
Study 20932805 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 304
Study 20932805 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 304
Study 19127582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmotor manifestations of Parkinson's disease
Number of subjects: 0
Study 15737664 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 42
Study 15737664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 14504313 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 0
Study 14504313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIg)
Number of subjects: 0
Study 14504313 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 14504313 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment with PE followed by IVIg or immunoabsorption followed by IVIg
Number of subjects: 0
Study 14504313 — intervention group
Group type: EXPERIMENTAL
Intervention: PE and IVIg
Number of subjects: 0
Study 12695731 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 52
Study 12695731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 10220006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional Assessment of Personality Pathology ‐ Basic Questionnaire (DAPP‐BQ)
Number of subjects: 136
Study 10220006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster membership associated with DSM‐IV diagnosis
Number of subjects: 136
Study 10220006 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical classification of eating‐disordered patients
Number of subjects: 136
Study 7529993 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 112
Study 7529993 — intervention group
Group type: COMPARATOR
Intervention: Observation only (Control)
Number of subjects: 112
Study 2212394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 10
Study 2212394 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil supplementation (n-6 fatty acids)
Number of subjects: 10
Study 2212394 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements (control for other variables)
Number of subjects: 10
Study 346042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA)
Number of subjects: 28
Study 346042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) after placebo
Number of subjects: 28
Study 346042 — intervention group
Group type: COMPARATOR
Intervention: Placebo after MPA
Number of subjects: 28
Study 346042 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA treated patients
Number of subjects: 28
Study 31399932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 87
Study 31399932 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 87
Study 28146397 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference Screw (IS)
Number of subjects: 80
Study 28146397 — intervention group
Group type: COMPARATOR
Intervention: Suture Anchor (SA)
Number of subjects: 80
Study 26288299 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic program
Number of subjects: 154
Study 26288299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychotherapeutic program)
Number of subjects: 154
Study 24355450 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (monthly videoconferences with a nurse for 32 weeks)
Number of subjects: 165
Study 24355450 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 165
Study 22335087 — intervention group
Group type: EXPERIMENTAL
Intervention: Height and weight adjusted dose of intrathecal hyperbaric bupivacaine (Group AD)
Number of subjects: 100
Study 22335087 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of intrathecal hyperbaric bupivacaine (2.2 ml) (Group FD)
Number of subjects: 100
Study 22335087 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of intrathecal hyperbaric bupivacaine (Group FD)
Number of subjects: 100
Study 19204412 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 18
Study 16895948 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative hyperinsulinemic normoglycemic clamp (regular insulin at a fixed rate of 0.1 IU.kg(‐1).h(‐1)) during 26 hours
Number of subjects: 44
Study 16895948 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care
Number of subjects: 44
Study 16895948 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative hyperinsulinemic normoglycemic clamp
Number of subjects: 44
Study 14745701 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexposure prophylaxis (PEP) for 10 days (n=410)
Number of subjects: 1110
Study 14745701 — intervention group
Group type: COMPARATOR
Intervention: Treatment of ill index cases with oseltamivir for 5 days (n=402)
Number of subjects: 1110
Study 11355938 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 125 monitoring during first-line chemotherapy
Number of subjects: 255
Study 11355938 — intervention group
Group type: EXPERIMENTAL
Intervention: New assessment criterion based on an increment of 2.5 times the baseline CA 125 concentration
Number of subjects: 255
Study 9276854 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hop for distance
Number of subjects: 20
Study 9276854 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple hop for distance
Number of subjects: 20
Study 9276854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over hop for distance
Number of subjects: 20
Study 9276854 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-m timed hop
Number of subjects: 20
Study 8133020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g DGLA
Number of subjects: 66
Study 8133020 — intervention group
Group type: COMPARATOR
Intervention: 1 g safflower oil
Number of subjects: 66
Study 8133020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium intake (70 mmol/day difference)
Number of subjects: 66
Study 8133020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium intake
Number of subjects: 66
Study 8133020 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist: hip ratio
Number of subjects: 66
Study 3315610 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 87
Study 3315610 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 87
Study 31358034 — intervention group
Group type: COMPARATOR
Intervention: Sham TEAS (Con group)
Number of subjects: 0
Study 31358034 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS during preoperative and intraoperative periods, sham TEAS postoperative (T1 group)
Number of subjects: 0
Study 31358034 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS during preoperative, sham TEAS intraoperative, TEAS postoperative (T2 group)
Number of subjects: 0
Study 31358034 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS before, during, and after operation (T3 group)
Number of subjects: 0
Study 31358034 — intervention group
Group type: COMPARATOR
Intervention: No TEAS (Con' group)
Number of subjects: 0
Study 31358034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham TEAS (T1' group)
Number of subjects: 0
Study 31358034 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hz TEAS (T2' group)
Number of subjects: 0
Study 31358034 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-Hz TEAS (T3' group)
Number of subjects: 0
Study 27888086 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 375
Study 25571933 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent group (n=12)
Number of subjects: 24
Study 25571933 — intervention group
Group type: COMPARATOR
Intervention: Supervised group (n=12)
Number of subjects: 24
Study 23347793 — intervention group
Group type: EXPERIMENTAL
Intervention: pegaptanib injection
Number of subjects: 235
Study 23347793 — intervention group
Group type: COMPARATOR
Intervention: sham injection
Number of subjects: 235
Study 21629200 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid L-carnitine (50 mg L-carnitine/kg bodyweight/day) for 3 months
Number of subjects: 30
Study 20144362 — intervention group
Group type: EXPERIMENTAL
Intervention: Levemir (insulin detemir) FlexPen
Number of subjects: 61
Study 20144362 — intervention group
Group type: COMPARATOR
Intervention: OptiClik (insulin glargine)
Number of subjects: 61
Study 17723076 — intervention group
Group type: EXPERIMENTAL
Intervention: S-albuterol 5 mg
Number of subjects: 22
Study 17723076 — intervention group
Group type: COMPARATOR
Intervention: Nebulized normal saline placebo
Number of subjects: 22
Study 14998380 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 9-36 microg
Number of subjects: 68
Study 14998380 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg
Number of subjects: 68
Study 14998380 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol > or =9 microg
Number of subjects: 68